993 / 1498
Current data would support the initiation of induction therapy with thalidomide,
lenalidomide, or bortezomib, plus hematopoietic stem-cell transplantation for fit
patients under the age of 65 years
Autologous stem-cell transplantation with a reduced-intensity conditioning regimen
should be considered for older patients or those with coexisting conditions
Conventional therapy combined with thalidomide, lenalidomide or bortezomib
should be administered in patients older han 65 years
Less intensive approaches should be considered in patients over 75 years
Treatment